AS-SPIK Antibody Epitope Specificity for Liver Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing liver cancer, such as serological tests, ultrasound, CT scans, and liver biopsy, are unreliable and invasive, and existing biomarkers like SPIK are hindered by low specificity and interference from other diseases, necessitating a more sensitive and specific diagnostic tool.
Innovation Solution
Development of monoclonal antibodies that specifically bind to the conformational epitope of AS-SPIK, distinguishing it from NS-SPIK, enabling early detection of liver cancer through ELISA tests and immunoconjugates for targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods (serological tests, ultrasound, CT scans, liver biopsy) are used for liver cancer detection, then detection capability is provided, but reliability is poor due to low sensitivity and operator error
Solution Approach 1:
The patent changes the detection parameter from conventional imaging and serological tests to a specific immunoassay detecting AS-SPIK protein. By targeting a specific protein marker with known differential expression in liver cancer versus normal tissue, the test achieves higher sensitivity and specificity for early-stage detection
Solution Approach 2:
The patent introduces AS-SPIK as an intermediary biomarker between liver cancer cells and the diagnostic test. This protein serves as a mediator that is selectively expressed in liver cancer, enabling indirect but reliable detection of the disease without requiring direct visualization or invasive biopsy
2Measurement precision
If imaging techniques (CT, MRI, angiography) are used for liver cancer detection, then visualization capability is provided, but cost increases and accuracy decreases for smaller early stage tumors
Solution Approach 1:
The patent replaces complex mechanical imaging systems (CT, MRI, angiography) with a biochemical detection system. Instead of using expensive imaging machinery to visualize tumors, the test uses antibody-based detection to identify cancer cells through their unique protein expression, simplifying the diagnostic process and reducing costs
3Reliability
If liver biopsy is used for distinguishing benign from malignant tumors, then diagnostic reliability is improved, but invasiveness and surgical requirement increase
Solution Approach 1:
The patent uses AS-SPIK as an intermediary marker that can be detected in blood or tissue samples without requiring direct biopsy of the tumor. This allows reliable differentiation between benign and malignant conditions through non-invasive sampling, eliminating the need for surgical intervention
Solution Approach 2:
The patent extracts the diagnostic information from the complex tissue sample analysis required in biopsies by isolating and detecting a specific protein marker (AS-SPIK) that is uniquely expressed in liver cancer. This extraction allows reliable diagnosis without performing the invasive biopsy procedure
4Measurement precision
If existing SPIK biomarker is used for liver cancer detection, then detection capability is provided, but specificity decreases due to elevation in other diseases like pancreatitis
Solution Approach 1:
The patent segments the SPIK protein into two distinct forms: NS-SPIK (normal secreted form) and AS-SPIK (abnormal secreted form with additional N-terminal residues). By targeting only the AS-SPIK form with specific antibodies, the test achieves high specificity for liver cancer while avoiding interference from other diseases that may elevate normal SPIK levels
Solution Approach 2:
The patent applies local quality by creating antibodies that recognize a specific local region (conformational epitope) of AS-SPIK that is unique to the abnormal form. This localized recognition ensures the test is sensitive to liver cancer while remaining specific, as the epitope is not present in NS-SPIK from other conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide high sensitivity and specificity for early-stage liver cancer detection, reducing interference from other diseases and improving diagnostic and treatment outcomes.
Implementation Method 1
monoclonal antibodies that specifically bind to the conformational epitope of AS-SPIK
Data Source
AI summary
Two classes of anti-AS-SPIK antibodies that specifically bind to one of two different conformational epitopes are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose and/or treat disorders characterized by the expression of AS-SPIK (e.g., liver cancer). Diagnostic methods and kits comprising the anti-AS-SPIK antibodies are also disclosed.